This landmark NEJM 2025 study showed that PRS-guided screening uncovers many high-risk prostate cancers missed by standard PSA pathways.
This landmark NEJM 2025 study showed that PRS-guided screening of men in the top genetic risk decile substantially improves detection of clinically significant prostate cancer, uncovering many high-risk cancers missed by standard PSA pathways, and establishes PRS-based risk stratification as a scalable, clinically impactful screening strategy.
Download File
Learn more